Staging, Treatment, and Future Approaches of Gallbladder Carcinoma
- 331 Downloads
Gallbladder cancer is the most common malignant cancer of the bile ducts and third most common gastrointestinal malignant in the world for public health. Its relatively low incidence and confused symptoms result in advanced disease at the time of presentation, contributing to poor prognosis and reduced survival associated with this disease. The main function of the gallbladder is to store excreted bile acids from the liver in preparation for a meal. Its main risk factor is prolonged exposure to biliary calculations, although bacterial infections and other inflammatory conditions are associated. Chronic inflammatory bowel conditions are associated with gallbladder cancer. T stage translates to identifying residual disease at reoperation for incidental gallbladder cancer and residual disease negatively affects survival.
It is the most common cancer of gallbladder, gallbladder cancer remains a rare disease. Gallbladder cancer is a rare disease that can be accidentally diagnosed after cholecystectomy or accidentally, often with more advanced disease. The prognosis is generally extremely poor and improvements in surgical resection of this approach have to be re-evaluated, while the role of chemotherapy and radiotherapy remains controversial.
KeywordsGallbladder Carcinoma Treatment Cholecystectomy Staging
I thank the review studies of GBC of participants who contributed to this work and I appreciate the supporting staff of Multidisciplinary Research Unit (MRU). I am highly thankful to the Principal, of Government Medical College, Haldwani, Nainital, Uttarakhand, India for giving a research place for this work.
This study was funded by Department of Health and Research, New Delhi, India.
Compliance with Ethical Standards
Conflict of Interest
None of the authors of this paper have a financial or personal relationship with other people or organization that could inappropriately influence or bias the content of the paper.
- 4.Destoll M. Rationis mendendi. In: Haak et Socios A et J Honkoop, editor. Nosocomio practico vendobonensi, Part I. Lugduni Batavorum; 1788Google Scholar
- 5.DeRegato JA, Spjut HJ. Digestive tract/accessory organo gallbladder. In: Ackerman LV, JA DR, editors. Cancer—diagnosis, treatment and prognosis. 5th ed. St Louis: CV Mosby; 1977. p. 599–604.Google Scholar
- 7.Moertel CG. The gallbladder. In: Holland JF, Frei III E, editors. Cancer medicine. 2nd ed. Philadelphia: Lea Ferbiger; 1982. 1782–1785.Google Scholar
- 12.Donohue JH, Nagorney DM, Grant CS, Tsushima K, Ilstrup DM, Adson MA. Carcinoma of the gallbladder: does radical resection improve outcome. Arch Surg. 1990;125(2):237–41. https://doi.org/10.1001/archsurg.1990.01410140115019.CrossRefPubMedGoogle Scholar
- 14.Sobin LH, Wittekind C. Digestive system: gallbladder. In: TNM classification of malignant tumours. 6th ed. New York: Wiley-Liss; 2002. p. 84–6.Google Scholar
- 16.Nevin JE, Moran TJ, Kay S, King R. Carcinoma of the gallbladder: staging, treatment and prognosis. Cancer. 1976;37(1):141–8. https://doi.org/10.1002/1097-0142(197601)37:1<141::AID-CNCR2820370121>3.0.CO;2-Y.CrossRefPubMedGoogle Scholar
- 17.Albores-Saavedra J, Henson DE, Sobin LH. The WHO histological classification of tumours of the gallbladder and extra hepatic bile duct a commentary on the second edition. Cancer. 1992;70(2):410–4. https://doi.org/10.1002/1097-0142(19920715)70:2<410::AID-CNCR2820700207>3.0.CO;2-R.CrossRefPubMedGoogle Scholar
- 20.Carriaga M, Henson DE. Liver, gallbladder, extra hepatic bile ducts and pancreas. Cancer. 1995;75(S1):171–90. https://doi.org/10.1002/1097-0142(19950101)75:1+<171::AID-CNCR2820751306>3.0.CO;2-2.CrossRefPubMedGoogle Scholar
- 32.Kuzmickiene I, Didziapetris R, Stukonis M. Cancer incidence in the workers cohort of textile manufacturing factory in Alytus, Lithuania. J Occup Environ Med. 2004;46(2):147–53. https://doi.org/10.1097/01.jom.0000111601.85534.12.CrossRefPubMedGoogle Scholar
- 39.Lin LL, Picus J, Drebin JA, Linehan DC, Solis J, Strasberg SM, et al. A phase II study of alternating cycles of split course radiation therapy and gemcitabine chemotherapy for inoperable pancreatic or biliary tract carcinoma. Am J Clin Oncol. 2005;28(3):234–41. https://doi.org/10.1097/01.coc.0000156920.11091.12.CrossRefPubMedGoogle Scholar
- 40.Ammori JB, Colletti LM, Zalupski MM, Eckhauser FE, Greenson JK, Dimick J, et al. Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas. J Gastrointest Surg. 2003;7(6):766–72. https://doi.org/10.1016/S1091-255X(03)00113-6.CrossRefPubMedGoogle Scholar
- 45.Doval D, Prabhash K, Patil S, Chaturvedi H, Goswami C, Vaid A, et al. Clinical and epidemiological study of EGFR mutations and EML4-ALK fusion genes among Indian patients with adenocarcinoma of the lung. Onco Targets Ther. 2015;8:117–23. https://doi.org/10.2147/OTT.S74820.PubMedPubMedCentralGoogle Scholar
- 46.Xuan YH, Choi YL, Shin YK, Kook MC, Chae SW, Park SM, et al. An immunohistochemical study of the expression of cell-cycle-regulated proteins p53, cyclin D1, RB, p27, Ki67 and MSH2 in gallbladder carcinoma and its precursor lesions. Histol Histopathol. 2005;20(1):59–66. https://doi.org/10.14670/HH-20.59.PubMedGoogle Scholar